糖肽类抗菌药物新品种—oritavancin
Oritavancin:a new member of glycopeptides
摘要
需氧革兰阳性球菌是细菌性感染的重要病原菌，自20世纪80年代末以来该类细菌所致感染呈上升趋势；尤为人们关注的是革兰阳性球菌耐药性的日趋严重，给感染性疾病的治疗带来严峻挑战。万古霉素和替考拉宁是目前用于治疗耐药革兰阳性菌感染的常用糖肽类药物，但随着临床应用的日益广泛，世界各地亦相继出现了万古霉素中介或耐药金葡菌（VISA、VRSA）以及万古霉素耐药肠球菌（VRE）。因此，万古霉素和替考拉宁已不能完全满足临床需要，有必要开发应用新的糖肽类药物。
出处
《中国感染与化疗杂志》
CAS
2007年第5期386-390,共5页
Chinese Journal of Infection and Chemotherapy
参考文献19
-
1Gerber J,Smirnov A,Wellmer A,et al.Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin[J].Antimicrob Agents Chemother,2001,45(7):2169-2172.
-
2Aeschlimann JR,Allen GP,Hershberger E,et al.Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model[J].Antimicrob Agents Chemother,2000,44(11):2991-2998.
-
3Chien J,Allerheiligen S,Phillips D,et al.Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphate (glycopeptide) in healthy men[C].In:Program and abstracts of the 38th interscience conference on antimicrobial agents and chemotherapy,San Diego,CA,September 24-27,1998.Washington,DC:American Society for Microbiology,1998:A-55.
-
4Van Bambeke F,Carryn S,Seral C,et al.Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages[J].Antimicrob Agents Chemother,2004,48(8):2853-2860.
-
5Boylan CJ,Campanale K,Iversen PW,et al.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection[J].Antimicrob Agents Chemother,2003,47(5):1700-1706.
-
6Noviello S,Ianniello F,Esposito S.In vitro activity of LY 333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci[J].J Antimicrob Chemother,2001,48(2):283-286.
-
7Zeckel ML,Preston DA,Allen BS.In vitro activities of LY 333328 and comparative agents against nosocomial gram-posit ive pathogens collected in a 1997 global surveillance study[J].Antimicrob Agents Chemother,2000,44(5):1370-1374.
-
8Fetterly GJ,Ong CM,Bhavnani SM,et al.Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose[J].Antimicrob Agents Chemother,2005,49(1):148-152.
-
9Van Bambeke F.Glycopeptides in clinical development:pharmacological profile and clinical perspectives[J].Curr Opin Pharmacol,2004,4(5):471-478.
-
10Torres-Viera C,Dembry LM.Approaches to vancomycin-resistant enterococci[J].Curr Opin Infect Dis,2004,17(6):541-547.
-
1刘敏.FDA要求oritavancin的安全性研究[J].国外药讯,2004(3):25-25.
-
2郭冬杰,张相林.氨基糖苷类和糖肽类抗菌药物的治疗药物监测[J].实用药物与临床,2013,16(2):145-147. 被引量：9
-
3李艳,刘晓阳.替考拉宁的临床应用进展及安全性评价[J].中国医院药学杂志,2008,28(12):1015-1017. 被引量：34
-
4刘红燕,卜艳丽.万古霉素所致白细胞减少文献概述[J].中国药物滥用防治杂志,2014(2):114-114. 被引量：4
-
5孙捍卫,降文兰,朱铁梁.万古霉素的国内应用和不良反应概况[J].武警医学院学报,2009,18(9):816-818. 被引量：8
-
6曹凤,黄明成,吴方建.新糖肽类抗菌药物奥利万星[J].中国药师,2015,18(7):1208-1210. 被引量：1
-
7糖肽类抗生素——Oritavancin[J].药学进展,2008,32(6):278-280.
-
8钱春艳,许建平,陈荣.糖肽类抗菌药物应用合理性调查分析[J].中华医院感染学杂志,2012,22(11):2392-2394. 被引量：2
-
9头孢菌素类抗生素[J].药物不良反应杂志,2005,7(2):119-119.
-
10抗菌药物临床应用指导原则[J].中国临床药学杂志,2005,14(3). 被引量：82
